You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Chiesi reinforces commitment to reducing emissions

In 2019, Chiesi committed €350m to develop the first carbon minimal pressurised metered dose inhaler (pMDI) to treat asthma and Chronic Obstructive Pulmonary Disease (COPD) by 2025, replacing the current hydrofluorocarbon propellant with a new propellant.